Brought to you by 
Hoechst AG buys remaining 43.5% of Roussel-Uclaf
13 Jul 1999
Executive Summary
Hoechst AG plans to buy the remaining 43.5% of Roussel-Uclaf that it does not already own, in a transaction valued at 16bn francs, or $3.6bn. Hoechst offered 1530 francs or $291 a share, which is a 12% premium over Roussel's average stock price.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hoechst AG buys remaining 43.5% of Roussel-Uclaf
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice